Jerome Birnbaum Appointed to Scientific Advisory Board of Ricerca, LLC

Apr 12, 2001, 01:00 ET from Ricerca, LLC

    CONCORD, Ohio, April 12 /PRNewswire/ -- Ricerca, LLC, a drug development
 company, has announced the appointment of Jerome Birnbaum, Ph.D., to its
 Scientific Advisory Board.  "Dr. Birnbaum is an acknowledged industry leader
 who has overseen highly productive drug discovery and development programs in
 two top-tier pharmaceutical companies," said Dr. Prabhavathi Fernandes,
 Ricerca CEO.  "His over 33 years of experience and successful management of
 drug discovery, research and development of the preclinical process will help
 guide Ricerca as we further expand into these areas."
     Dr. Birnbaum is co-founder and an active member of the board of directors
 of Achillion Pharmaceuticals, Inc., New Haven, CT, a biotechnology company
 involved with the discovery, development and commercialization of innovative
 anti-infective agents.
     Prior to co-founding Achillion, Dr. Birnbaum was senior vice president for
 strategic R&D operations and a member of the Institute Executive Committee at
 the Pharmaceutical Research Institute of Bristol-Myers Squibb.  When Bristol-
 Myers merged with Squibb, he became the senior vice president for
 pharmaceutical development, the largest section of the R&D organization of BMS
 Pharmaceutical Research Institute.  Before joining Bristol-Myers Squibb, Dr.
 Birnbaum was vice president, microbiology and agricultural research and
 director, exploratory biological research, as well as a member of the Research
 Management Council and the Development Coordinating Committee at the Merck
 Sharp and Dohme Research Labs, Merck & Co., Inc.   In recognition of his
 unique experience, he serves on the Scientific Advisory Board of a number of
 biotech companies, including Versicor Inc. and Sunesis Pharmaceuticals.  He
 also serves as a director for New Brunswick Scientific Company, Minerva
 Pharmaceutical, Inc., and the American Society for Microbiology.  He serves on
 numerous governmental agencies, including the National Institute for Allergy
 and Infectious Diseases.
     Ricerca, LLC, a drug development company, offers technical expertise in
 late stage discovery through IND development.  The company speeds drug lead
 optimization and preclinical candidate selection through advanced Absorption,
 Distribution, Metabolism, Excretion and Toxicology (ADMET) technologies, and
 then helps its customers rapidly develop the preclinical Chemistry,
 Manufacturing and Controls (CMC) and nonclinical safety data to support filing
 of the Investigational New Drug application (IND).  When the drug enters human
 clinical investigations, Ricerca provides continued critical chemical process
 development and optimization, API production and clinical trial sample
 bioanalysis.  The company, privately owned by SG Capital Partners, LLC, New
 York, NY and Venture Biologics, LLC, Plymouth Meeting, PA is located near
 Cleveland, Ohio and has over 240 employees.
 
 

SOURCE Ricerca, LLC
    CONCORD, Ohio, April 12 /PRNewswire/ -- Ricerca, LLC, a drug development
 company, has announced the appointment of Jerome Birnbaum, Ph.D., to its
 Scientific Advisory Board.  "Dr. Birnbaum is an acknowledged industry leader
 who has overseen highly productive drug discovery and development programs in
 two top-tier pharmaceutical companies," said Dr. Prabhavathi Fernandes,
 Ricerca CEO.  "His over 33 years of experience and successful management of
 drug discovery, research and development of the preclinical process will help
 guide Ricerca as we further expand into these areas."
     Dr. Birnbaum is co-founder and an active member of the board of directors
 of Achillion Pharmaceuticals, Inc., New Haven, CT, a biotechnology company
 involved with the discovery, development and commercialization of innovative
 anti-infective agents.
     Prior to co-founding Achillion, Dr. Birnbaum was senior vice president for
 strategic R&D operations and a member of the Institute Executive Committee at
 the Pharmaceutical Research Institute of Bristol-Myers Squibb.  When Bristol-
 Myers merged with Squibb, he became the senior vice president for
 pharmaceutical development, the largest section of the R&D organization of BMS
 Pharmaceutical Research Institute.  Before joining Bristol-Myers Squibb, Dr.
 Birnbaum was vice president, microbiology and agricultural research and
 director, exploratory biological research, as well as a member of the Research
 Management Council and the Development Coordinating Committee at the Merck
 Sharp and Dohme Research Labs, Merck & Co., Inc.   In recognition of his
 unique experience, he serves on the Scientific Advisory Board of a number of
 biotech companies, including Versicor Inc. and Sunesis Pharmaceuticals.  He
 also serves as a director for New Brunswick Scientific Company, Minerva
 Pharmaceutical, Inc., and the American Society for Microbiology.  He serves on
 numerous governmental agencies, including the National Institute for Allergy
 and Infectious Diseases.
     Ricerca, LLC, a drug development company, offers technical expertise in
 late stage discovery through IND development.  The company speeds drug lead
 optimization and preclinical candidate selection through advanced Absorption,
 Distribution, Metabolism, Excretion and Toxicology (ADMET) technologies, and
 then helps its customers rapidly develop the preclinical Chemistry,
 Manufacturing and Controls (CMC) and nonclinical safety data to support filing
 of the Investigational New Drug application (IND).  When the drug enters human
 clinical investigations, Ricerca provides continued critical chemical process
 development and optimization, API production and clinical trial sample
 bioanalysis.  The company, privately owned by SG Capital Partners, LLC, New
 York, NY and Venture Biologics, LLC, Plymouth Meeting, PA is located near
 Cleveland, Ohio and has over 240 employees.
 
 SOURCE  Ricerca, LLC